COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY

被引：1
|
作者：
Toumi, M. [1 ]
Lamure, M. [1 ]
Grishchenko, M. [2 ]
Cochran, J. [2 ]
Rive, B. [1 ]
机构：
[1] Univ Lyon 1, F-69622 Villeurbanne, France
[2] Lundbeck SAS, Paris, France
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74819-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A370 / A370
页数：1
相关论文
共 50 条
  • [41] Memantine improves independence in moderate to severe Alzheimer's disease
    Guilhaume, C
    Lundbeck, H
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S207 - S208
  • [42] Memantine approved to treat moderate to severe Alzheimer’s disease
    Karen Marder
    Current Neurology and Neuroscience Reports, 2004, 4 (5) : 349 - 350
  • [43] Memantine enhances autonomy in moderate to severe Alzheimer's disease
    Rive, B
    Vercelletto, M
    Damier, FD
    Cochran, J
    François, C
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (05) : 458 - 464
  • [44] Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
    Howard, Robert
    McShane, Rupert
    Lindesay, James
    Ritchie, Craig
    Baldwin, Ashley
    Barber, Robert
    Burns, Alistair
    Dening, Tom
    Findlay, David
    Holmes, Clive
    Hughes, Alan
    Jacoby, Robin
    Jones, Rob
    Jones, Roy
    McKeith, Ian
    Macharouthu, Ajay
    O'Brien, John
    Passmore, Peter
    Sheehan, Bart
    Juszczak, Edmund
    Katona, Cornelius
    Hills, Robert
    Knapp, Martin
    Ballard, Clive
    Brown, Richard
    Banerjee, Sube
    Onions, Caroline
    Griffin, Mary
    Adams, Jessica
    Gray, Richard
    Johnson, Tony
    Bentham, Peter
    Phillips, Patrick
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10): : 893 - 903
  • [45] Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
    Hansson-Hedblom, Amanda
    Almond, Chrissy
    Borgstrom, Fredrik
    Sly, Indeg
    Enkusson, Dana
    Buchholt, Anders Troelsgaard
    Karlsson, Linda
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [46] Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
    Amanda Hansson-Hedblom
    Chrissy Almond
    Fredrik Borgström
    Indeg Sly
    Dana Enkusson
    Anders Troelsgaard Buchholt
    Linda Karlsson
    Cost Effectiveness and Resource Allocation, 16
  • [47] Memantine treatment benefits the language function in patients with moderate to severe Alzheimer's disease
    Ferris, S.
    Ihl, R.
    Robert, P.
    Winblad, B.
    Gauthier, S.
    Tennigkeit, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 357 - 357
  • [48] Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease
    Wirth, Y
    Doody, RS
    Schmitt, FA
    Möbius, HJ
    Stöffler, A
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S207 - S207
  • [49] Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    Doody, R
    Wirth, Y
    Schmitt, F
    Möbius, HJ
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 18 (02) : 227 - 232
  • [50] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
12345